

ORTIN GLOBAL LIMITED

(Formerly Known as ORTIN LABORATORIES LIMITED)
CIN: L24110TG1986PLC006885



Date: 26-05-2025

To

1. BSE Limited, P.J. Towers, Dalal Street, Mumbai-400001 Scrip code: 539287	2. National Stock Exchange of India Limited, Exchange Plaza, Bandra- Kurla Complex, Mumbai-400051 Symbol: ORTINGLOBE
---	--

Sub: Outcome of Board Meeting held on 26-05-2025 under Regulation 30 of SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015

Dear Sir/Madam,

With reference to the above-mentioned subject, this is to inform the Exchanges that the Board of Directors of Ortin Global Limited (Formerly Known as Ortin Laboratories Limited) at its meeting held on Monday, 26-05-2025 at 3.00 p.m. at the Registered Office of the Company, inter-alia, considered and approved the following:

1. Approval of Audited financial results of the company along with the Statutory Audit Report and Declaration as per Regulation 33 of SEBI (LODR) Regulations, 2015, for the quarter and financial year ended 31.03.2025. **(Enclosed)**
2. Based on the recommendation of the Audit Committee of the Company, the Board has considered and approved the appointment of M/s. Aakanksha Dubey & Co, Practicing Company Secretaries as Secretarial Auditors of the Company for a period of five (5) years i.e, for the financial years 2025-26 to 2029-30 **(Brief profile is provided)**
3. Approved the Resignation tendered by Mr. Gopal Reddy Bheemreddy (DIN: 06716560), Independent Director of the Company with immediate effect, due to his advancing age. He has confirmed that there are no other material reasons for his resignation other than that mentioned in his resignation letter. **(Resignation Letter is enclosed)**
4. Based on the recommendation of the Nomination and Remuneration Committee of the Company, approved appointment of Ms. MOUNIKA PAMMI (DIN: 11111376) as an Additional Director in the category of Independent Director of the company with immediate effect for a term of 5 years, subject to the approval of the shareholders of the company. **(Brief profile is attached)**

Regd. Office: Mayfair Gardens, 8-2-682/3/A & 3B, Flat no-201, 2nd Floor, Road No-12, Banjara Hills, Hyderabad- 500034, Telangana, India.
Email: info@ortinlabsindia.com Website: www.ortinlabsindia.com
Ph. No. +91 9052011118

ORTIN GLOBAL LIMITED

(Formerly Known as ORTIN LABORATORIES LIMITED)

CIN: L24110TG1986PLC006885



5. Reconstitution of Committees of the Board as under:

AUDIT COMMITTEE:

S-No.	Name	Designation
1	Ms. Pottur Sujatha	Chairperson
2	Mr. Murali Krishna Rayaprolu	Member
3	Ms. MOUNIKA PAMMI	Member

NOMINATION & REMUNERATION COMMITTEE

S-No.	Name	Designation
1	Ms. Pottur Sujatha	Chairperson
2	Mr. Murali Krishna Rayaprolu	Member
3	Ms. MOUNIKA PAMMI	Member

STAKEHOLDERS RELATIONSHIP COMMITTEE

S-No.	Name	Designation
1	Mr. Murali Krishna Rayaprolu	Chairman
2	Ms. Pottur Sujatha	Member
3	Ms. MOUNIKA PAMMI	Member

Disclosure of information with regard to the appointment of above mentioned auditor & Director and resignation of Director as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Para-A of Schedule-III are provided below as **Annexure-A**

The Meeting Concluded at 6.00 PM

We request you to take note of the same in your records.

Thanking you.

**Yours sincerely,
For Ortin Global Limited
(formerly known as Ortin Laboratories Limited)**

MURALI
KRISHNA
MURTHY SANKA
Digitally signed by MURALI
KRISHNA MURTHY SANKA
Date: 2025.05.26 18:09:49
+05'30'

**S. Murali Krishna Murthy
Managing Director
DIN: 00540632**

Encl: as mentioned above:

Regd. Office: Mayfair Gardens, 8-2-682/3/A & 3B, Flat no-201, 2nd Floor, Road No-12, Banjara Hills, Hyderabad- 500034, Telangana, India.
Email: info@ortinlabsindia.com Website: www.ortinlabsindia.com
Ph. No. +91 9052011118

ORTIN GLOBAL LIMITED

(Formerly Known as ORTIN LABORATORIES LIMITED)
CIN: L24110TG1986PLC006885



ANNEXURE-A

Details as required under Part A of Schedule III and Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circulars No. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023 and No. SEBI/HO/CFD/CFDPoD1/P/CIR/2023/123 dated July 13, 2023, concerning the appointments and resignation is provided below:

S.No	Particulars	Aakanksha Dubey & Co.	Ms. MOUNIKA PAMMI	Mr. Gopal Reddy Bheemreddy
1	Reason for Change viz. appointment, re-appointment, resignation, removal, death or otherwise	Appointment of M/s. Aakanksha Dubey & Co, Practicing Company Secretaries as Secretarial Auditors of the Company	Appointment of Ms. MOUNIKA PAMMI as Independent Director of the company	Mr. Gopal Reddy Bheemreddy has resigned from the position of Independent Director of the company due to his advancing age
2	Date of Appointment / Cessation	Appointed on 26-05-2025	Appointed on 26-05-2025	Resigned with immediate effect from close of business hours on 26-05-2025
3	Terms of appointment	For a period of five (5) years i.e, for the financial years 2025-26 to 2029-30	For a period of five (5) years	NA
4	Brief profile (in case of appointment)	M/s. Aakanksha Dubey & Co, Practicing Company Secretaries registered with the Institute of Company Secretaries of India. The Firm is being managed by a team of competent and experienced professionals with rich experience.	Attached	NA
5	Disclosure of Relationships with other Directors (in case of appointment)	NA	Nil	NA

Regd. Office: Mayfair Gardens, 8-2-682/3/A & 3B, Flat no-201, 2nd Floor, Road No-12, Banjara Hills, Hyderabad- 500034, Telangana, India.
Email: info@ortinlabsindia.com Website: www.ortinlabsindia.com
Ph. No. +91 9052011118

ORTIN GLOBAL LIMITED

(Formerly Known as ORTIN LABORATORIES LIMITED)
CIN: L24110TG1986PLC006885



6.	Shareholding, if any in the company	Nil	Nil	NA
7.	Affirmation that the Director being appointed is not debarred from holding the office of director by virtue of any SEBI order or any other such authority	NA	To the best of our knowledge and information, we hereby affirm that Ms. MOUNIKA PAMMI is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority.	NA
8.	Name of listed entities in which the resigning Director holds directorship	NA	Nil	Nil

For Ortin Global Limited
(formerly known as Ortin Laboratories Limited)

MURALI KRISHNA
KRISHNA MURTHY SANKA
MURTHY SANKA
Date: 2025.05.26 18:10:22
+05'30'

S. Murali Krishna Murthy
Managing Director
DIN: 00540632

Regd. Office: Mayfair Gardens, 8-2-682/3/A & 3B, Flat no-201, 2nd Floor, Road No-12, Banjara Hills, Hyderabad- 500034, Telangana, India.
Email: info@ortinlabsindia.com Website: www.ortinlabsindia.com
Ph. No. +91 9052011118



INDEPENDENT AUDITOR'S REPORT

TO THE BOARD OF DIRECTORS OF ORTIN GLOBAL LIMITED

Report on the audit of the Financial Results

Opinion:

We have audited the accompanying quarterly and year to date financial results of **Ortin Global Limited** (the company) for the quarter ended 31.03.2025 and for the year ended 31.03.2025 attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these financial results:

- i. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India including the Ind AS, of the net loss and other comprehensive income and other financial information for the quarter ended 31.03.2025 as well as the year-to-date results for the period from 01.04.2024 to 31.03.2025.


Basis for Opinion:

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended to the extent applicable. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibilities for the Financial Results:

These quarterly financial results as well as the year-to-date financial results have been prepared on the basis of the financial statements.

The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit/loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This





responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Results:

Our objectives are to obtain reasonable assurance about whether the financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the





MATHESH & RAMANA
CHARTERED ACCOUNTANTS

financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.


We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter:

The financial results include the results for the quarterly ended 31.03.2025, being the balancing figure between the audited figures in respect of the full financial year ended 31.03.2025 and the published unaudited year-to-date figures of the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations.

For **MATHESH & RAMANA**
CHARTERED ACCOUNTANTS



B. V. RAMANA REDDY
M. No. 026967 Partner

Place: Hyderabad

Date: 26.05.2025

UDIN: 25026967BMMLTR7258

ORTIN GLOBAL LIMITED

(Formerly Known as ORTIN LABORATORIES LIMITED)

CIN:L24110TG1986PLC006885



STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31.03.25

S No	Particulars	Quarter Ended			Year Ended	
		31.03.2025	31.12.2024	31.03.2024	31.03.2025	31.03.2024
		Audited	Un Audited	Audited	Audited	Audited
1	a) Net Sales / Income from Operations	4.53	3.35	14.48	34.22	211.15
2	b) Other Operating Income	4.10	0.00	16.42	4.13	17.34
3	Total Income (1+2)	8.63	3.35	30.90	38.35	228.49
4	Expenditure					
	a) Cost of Material Consumed	1.88	3.15	8.27	18.42	238.17
	b) Employee Benefits Expenses	3.49	4.29	8.74	15.34	56.21
	c) Changes in inventory	-0.99	0.03	7.82	3.04	133.35
	d) Finance cost	0.02	-1.46	7.61	0.27	48.20
	e) Depreciation	0.00	0.21	4.82	1.17	22.84
	f) Other Expenditure	20.35	9.19	311.44	85.78	437.13
	Total Expenses	24.75	15.41	348.70	124.02	935.90
5	Profit / (Loss) before Exceptional Items and tax (3-4)	-16.12	-12.06	-317.80	-85.67	-707.41
6	Exceptional Items	0.00	-1.92	0.00	-1.92	0.11
7	Profit / (Loss) before tax (5-6)	-16.12	-10.14	-317.80	-83.75	-707.52
8	Tax Expense					
	a) Current Tax	0.00	0.00	129.40	0.00	129.40
	b) Deferred Tax	0.29	0.55	-32.72	0.89	-32.82
9	Profit / (Loss) after tax for the period from continuing operations (7-8)	-16.41	-10.69	-414.48	-84.64	-804.10
10	Other comprehensive income					
	(i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
	(ii) Tax on items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
	(i) Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00
		0.00	0.00	0.00	0.00	0.00
11	Total comprehensive income for the period (comprising Profit(Loss) and other comprehensive income for the period (9+10)	-16.41	-10.69	-414.48	-84.64	-804.10

[Handwritten signature]

Regd. Office: Mayfair Gardens, 8-2-682/3/A & 3B, Flat no-201, 2nd Floor, Road No. 12, Banjara Hills, Hyderabad- 500034, Telangana, India.

Email: info@ortinlabsindia.com

Website: www.ortinlabsindia.com

Ph. No. +91 9052011118



ORTIN GLOBAL LIMITED

(Formerly Known as ORTIN LABORATORIES LIMITED)



CIN:L24110TG1986PLC006885						
12	Paid-up equity share capital (Face value of Rs. 10/- per share)	813.14	813.14	813.14	813.14	813.14
13	Other Equity				-615.39	-530.75
14	Earnings Per Share (EPS)					
	a) Basic and diluted EPS before extraordinary items for the period, for the year to date and for the previous year (not to be annualised)	-0.20	-0.13	-5.10	-1.04	-9.89
	b) Basic and diluted EPS after Extraordinary items for the period, for the year to date and for the previous year (not to be annualised)	-0.20	-0.13	-5.10	-1.04	-9.89

Notes:

- (i) The above results have been recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 26th May, 2025.
- (ii) The financial results of the company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended by the Companies (Indian Accounting Standards) (Amendment) Rules 2016.
- (iii) The figures for the quarter ended March 31, 2025 and March 31, 2024 are balancing figures between the audited figures in respect of the full financial year and year to date figures upto the third quarter for the respective period which were subject to limited review.
- (iv) Previous period figures have been regrouped / rearranged wherever necessary, to make them comparable.
- (v) The entire operations of the Company relate to only one segment hence segmental reporting as per Ind AS 108 is not applicable.
- (vi) The Statutory Auditors of the Company have carried out "Audit" of the above audited financial results and their Report has been placed before the Board at the said Meeting as required under Regulation 33 of SEBI (LODR) Regulations, 2015.
- (vii) The results are also available on the website of the Company www.ortinlabsindia.com.

Place: Hyderabad

Date: 26.05.2025



For and on Behalf of the Board of Directors

ORTIN GLOBAL LIMITED

S.MURALI KRISHNA MURTHY

Managing Director

DIN: 00540632

Regd. Office: Mayfair Gardens, 8-2-682/3/A & 3B, Flat no-201, 2nd Floor, Road No-12, Banjara Hills, Hyderabad- 500034, Telangana, India.

Email: info@ortinlabsindia.com

Website: www.ortinlabsindia.com


Ph. No. +91 9052011118

ORTIN GLOBAL LIMITED
Formerly known as **ORTIN LABORATORIES LIMITED**

Audited Statement of Assets and Liabilities as at March, 2025

Rs in Lakhs

Particulars	Standalone	
	As At 31st March, 2025	As At 31st March, 2024
I. ASSETS		
<u>(1) Non-Current Assets</u>		
(a) Property, Plant and Equipment	0.36	1.17
(b) Intangible Assets	-	-
(c) Capital Work in Progress	-	-
	0.36	1.17
(d) Financial Assets		
(i) Investments	-	-
(ii) Trade Receivables	-	-
(iv) Others Financial Assets	36.97	23.37
(e) Deferred Tax Asset	6.53	7.42
(f) Long Term Loans and Advances	-	-
	43.50	30.79
<u>(2) Current Assets</u>		
(a) Inventories	1.98	5.02
(a) Financial Assets		
(i) Trade Receivables	26.12	176.65
(ii) Cash and Cash Equivalents	37.37	45.93
(iii) Bank balances other than (ii) above	-	188.33
(iv) Loans and Advances	-	-
(v) Other Financial Assets	-	-
(b) Current Tax Assets (Net)	-	-
(c) Other Current Assets	268.76	218.54
	334.23	634.47
Total Assets	378.09	666.43



II. EQUITY AND LIABILITIES:-		
<u>EQUITY</u>		
(a) Equity Share Capital	813.14	813.14
(b) Other Equity	(615.39)	(530.75)
	197.75	282.39
<u>LIABILITIES</u>		
<u>(1) Non-Current Liabilities</u>		
(a) Financial Liabilities		
(i) Borrowings	25.00	180.23
(b) Provisions	-	-
(c) Deferred Tax Liabilities	-	-
(d) Non Current Liabilities	-	-
	25.00	180.23
<u>(2) Current Liabilities</u>		
(a) Financial Liabilities		
(i) Borrowings	-	-
(ii) Trade Payables	4.23	7.82
(iii) Other Financial Liabilities	-	-
(b) Other Current Liabilities	151.11	175.73
(c) Provisions	-	2.42
(d) Current Tax Liabilities (Net)	-	17.84
	155.34	203.81
Total Equity & Liabilities	378.09	666.43

Place : Hyderabad

Date : 26.05.2025

For and on Behalf of the Board of Directors
ORTIN GLOBAL LIMITED



S. Murali Krishna Murthy

S. MURALI KRISHNA MURTHY

Managing Director

DIN: 00540632

ORTIN GLOBAL LIMITED
Formerly known as ORTIN LABORATORIES LIMITED


AUDITED CASH FLOW STATEMENT FOR THE YEAR ENDED 31.03.2025

Rs in Lakhs

Particulars	31.03.2025	31.03.2024
Cash Flows from Operating Activities		
Net profit before tax	(83.75)	(707.52)
Adjustments for :		
Finance cost recognised in profit & loss	0.27	48.20
Depreciation	1.17	22.84
Profit / Loss on Sale of Assets	-	214.97
Operating profit before working capital changes	(82.31)	(421.51)
Movements in Working Capital :		
(Increase)/Decrease in Trade and Other Receivables	150.53	165.09
(Increase)/Decrease in inventories	3.04	254.82
(Increase)/Decrease in Other financial assets	(13.60)	3.69
(Increase)/Decrease in Other assets	-	-
(Increase)/Decrease in Other Assets	(50.22)	(192.06)
Increase/(Decrease) in Trade Payables	(3.59)	(146.90)
Increase/(Decrease) in Other financial liabilities	-	-
Increase/(Decrease) in Other Current liabilities	(42.46)	8.76
Increase/(Decrease) in Provisions	(2.42)	(21.20)
Changes in Working Capital	41.28	72.20
Cash generated from operations	(41.03)	(349.31)
Direct Taxes Paid	-	(129.40)
Net Cash from operating activities (A)	(41.03)	(478.71)
Cash flows from Investing Activities		
Purchase of Fixed Assets	(0.36)	1,200.02
changes in investments	-	-
Net Cash used in Investing Activities (B)	(0.36)	1,200.02
Cash flows from Financing Activities		
proceeds from issue of equity investments of company	-	-
Repayment/(Proceeds) of/from borrowings	(155.23)	(116.03)
Finance cost	(0.27)	(48.20)
Increase/decrease in short term borrowings	-	-
(Increase)/Decrease in Other bank balances	188.33	(184.72)
Net Cash used in Financing Activities (C)	32.83	(348.95)
Net Increase/(Decrease) in cash and cash equivalents (A+B+C)	(8.56)	372.36
Cash and Cash equivalents at the beginning of the year	45.93	(326.43)
Cash and Cash equivalents at the ending of the year	37.37	45.93

Particulars	31.03.2025	31.03.2024
Cash and Cash Equivalents	37.37	45.93
Less: Short Term Borrowings From Banks	-	-
	37.37	45.93

Place : Hyderabad
Date : 26.05.2025



For and on Behalf of the Board of
Directors

ORTIN GLOBAL LIMITED

S. MURALI KRISHNA MURTHY
Managing Director
DIN: 00540632

ORTIN GLOBAL LIMITED

(Formerly Known as ORTIN LABORATORIES LIMITED)
CIN:L24110TG1986PLC006885



To,

Date: 26-05-2025

1. BSE Limited P.J. Towers, Dalal Street, Mumbai-400 001 Scrip Code: 539287	2. National Stock Exchange of India Limited Exchange plaza, C-1, Block G, BandraKurla Complex, Bandra, East, Mumbai-400 051, Maharashtra Symbol: ORTINGLOBE
--	---

Sub: Declaration pursuant to regulation 33 (3) (d) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 for Unmodified Opinion.

Ref: Ortin Global Limited

Dear Sir/Madam,

I, S. Murali Krishna Murthy, Managing Director of OrtinGlobal Limited hereby declare that, the Statutory Auditors of the company, M/s.Mathesh&Ramanahave issued an Audit Report with unmodified/unqualified opinion on Audited Financial Results of the companyfor the quarter and year ended 31stMarch, 2025.

I further declare that the audited financial results of the company for the quarter and year ended 31-03-2025 do not contain any false or misleading statements or figures and do not omit any material fact which may make the statements or figures contain therein misleading.

This declaration is issued in compliance of Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you.

**Yours sincerely,
For Ortin Global Limited
(formerly known as Ortin Laboratories Limited)**

**S. Murali Krishna Murthy
Managing Director
DIN: 00540632**

**Regd. Office: Mayfair Gardens, 8-2-682/3/A & 3B, Flat no-201, 2nd Floor, Road No-12,
Banjara Hills, Hyderabad- 500034, Telangana, India.**

Email:info@ortinlabsindia.com

Website:www.ortinlabsindia.com

Ph. No. +91 9052011118

To
The Board of Directors
M/s. Ortin Global Limited
(formerly known as Ortin Laboratories Limited)
Mayfair Gardens, 8-2-682/3/A & 3B, Flat No. 201,
2nd Floor, Road No.12, Banjara Hills, Hyderabad,
Khairatabad, Telangana, India, 500034

Date: 26.05.2025

Sub: Confirmation on Reason for Resignation.


Further, pursuant to my resignation letter dated 26.05.2025, I hereby confirm that pursuant to Schedule III Part A Clause 7B(ii) of the SEBI (Listing Obligations and Disclosure Requirements) (Amendments) Regulations, 2018, there are no other material reasons other than those provided in my resignation letter.

Additional details in connection to my resignation from the Company are as below:

S. No.	Particulars	Comment
1.	Detailed reasons for the resignation.	Due to my advancing age, I hereby tender my resignation from the independent Directorship of the company.

Thanking you.

Yours faithfully,


Gopal Reddy Bheemreddy
(DIN:06716560)

To
The Board of Directors
M/s. Ortin Global Limited
(formerly known as Ortin Laboratories Limited)
Mayfair Gardens, 8-2-682/3/A & 3B, Flat No. 201,
2nd Floor, Road No.12, Banjara Hills, Hyderabad,
Khairatabad, Telangana, India, 500034

Date: 26.05.2025

Sub: Resignation from the position of Independent Director

Dear Sir/Madam,

It has been my privilege to serve on the board of directors of the company as an independent Director.


Due to my advancing age, I hereby tender my resignation from the independent Directorship of the company. Kindly accept this resignation letter as independent Director of the company including the board committees and relieve me from my duties with effect from 26.05.2025.

I confirm that there are no material reasons for my resignation other than stated herein.

Kindly acknowledge the receipt of this resignation letter and arrange to submit the necessary forms with the office of the Registrar of Companies (ROC) and Stock Exchanges to the effect.

Thanking you.

Yours faithfully,


Gopal Reddy Bheemreddy
(DIN:06716560)

To
The Board of Directors
M/s. Ortin Global Limited
(formerly known as Ortin Laboratories Limited)
Mayfair Gardens, 8-2-682/3/A & 3B, Flat No. 201,
2nd Floor, Road No.12, Banjara Hills, Hyderabad,
Khairatabad, Telangana, India, 500034

Date: 26.05.2025

Sub: Names of listed entities in which the resigning director holds directorships


Dear Sir/Madam,

Further, pursuant to my resignation letter dated 26.05.2025, I hereby confirm that pursuant to Schedule III Part A Clause 7B (ia) of the SEBI (Listing Obligations and Disclosure Requirements) (Amendments) Regulations, 2018, I hold directorships in any other company is as follows:

Name of the Company	Designation	Member of Board Committee
-	-	-

Thanking you.

Yours faithfully,


Gopal Reddy Bheemreddy
(DIN:06716560)

Profile:**PAMMI MOUNIKA REDDY**

MBA (Marketing) | Consultant | Strategic Advisor
Former Managing Director – MNRG Technologies
Hyderabad, Telangana, India
Mobile: +91 9704084785
Email: pammimounika06@gmail.com

Professional Summary

Pammi Mounika Reddy is an accomplished professional with over 15 years of leadership experience spanning marketing, administration, insurance, CSR fund management and strategic consulting. She holds an MBA in Marketing and a proven track record in operational efficiency and business development, she brings a high degree of strategic insight and governance capability to the boardroom.

Ms. Reddy previously served as the Managing Director of MNRG Technologies, where she led various innovation-driven initiatives aligned with national priorities. Her broad exposure to corporate leadership, combined with her consulting background, equips her to offer independent oversight, critical thinking, and business foresight as a board member.

Her career includes senior roles across leading insurance companies, where she consistently delivered strong business outcomes, built high-performing teams, and led multi-location operations with compliance and efficiency.

A passionate advocate for social development, she led the PMKEY Scream Project (2014–2016), creating employment and sustainable livelihoods for over 200 women. Her professional journey demonstrates an unwavering commitment to ethical leadership, transparency, and stakeholder value creation.

Core Competencies

- Corporate Strategy & Governance
 - Marketing & Business Development
 - Risk & Operations Management
 - Financial Oversight & Compliance
 - Team Building & Leadership Development
 - Stakeholder Engagement & Business Transformation
 - Insurance & Healthcare Sector Expertise
-

Professional Experience

Consultant & Strategic Advisor

Advising organizations on business optimization, marketing strategies, and operational efficiency with a focus on scalable, sustainable growth.

Former Managing Director, MNRG Technologies

Led the organization through strategic transformation and digital innovation initiatives, aligning with emerging business models and market trends.

Senior Area Manager, Future Generali India Life Insurance

Drove regional performance to national leadership levels; recognized as the top-performing manager across India for multiple years.

Manager, Bajaj Allianz Life Insurance

Streamlined processes and improved efficiency across multiple branches while mentoring and developing frontline teams.

Office Head, DHFL Pramerica Life Insurance

Oversaw administrative and operational functions with a focus on driving growth and improving cost structures. Managed rural health CSR programs and insurance outreach initiatives.

Associate Branch Sales Manager, Bharti AXA Life Insurance

Led branch-level performance improvements and implemented customer-centric marketing campaigns in collaboration with healthcare partners.

Admin Officer, APMAS

Managed key administrative functions, budgeting, and team coordination in a development-focused organization. Directed multiple grassroots CSR initiatives such as water harvesting, SHG development, and sustainable farming practices.

Educational Qualifications

- **MBA (Marketing)**
- **Bachelor of Commerce**

Board Readiness & Compliance

Ms. Reddy meets the eligibility criteria for appointment as an **Independent Director** under Section 149(6) of the Indian Companies Act, 2013. She offers:

- Independence of thought and decision-making
- A commitment to fiduciary responsibilities
- Deep understanding of business operations and compliance
- Strong business judgment and ethical governance

- Experience across regulated industries
- Independence from company operations and management

Notable Achievements

- Consistently ranked #1 in national leadership rankings at Future Generali
- Built and scaled successful teams with year-on-year promotions
- Recognized for operational excellence and leadership performance
- Successfully executed marketing and business strategies across diverse regions

Languages Known

- English, Hindi, Telugu

Personal Information

- **Date of Birth:** 17 June 1983
- **Marital Status:** Married
- **Location:** Hyderabad, Telangana